TY  - BOOK
AU  - Cabungcal, Maybelle S., MD.
AU  - Bitun, Humphrey C., MD.
TI  - Factors associated with her-2/neu protein overexpression among female patients with invasive ductal carcinoma of FEU-NRMF Medical Center from January to December 2012 / 
AV  - PATH 2013 0003 
PY  - 2013///
CY  - Fairview, Quezon City
PB  - Department of Pathology, FEU-NRMF
N1  - Includes appendices and bibliographical references; RESDPLD
N2  - Abstract:  Her-2/neu is a proto-oncogene that is amplified or overexpresssed in 15 to 30% of invasive breast cancers.  The purpose of this study is to determine the prevalence of Her-2/neu overexpression among female patients of FEU-NRMF Medical Center with invasive ductal carcinoma from January to December 2012.  The study also aims to determine the association of Her-2/neu overexpression with tumor size, lymph node status, histologic grade of the tumor, and risk factors such as patent`s age at the time of diagnosis and presence of patient`s fierst degree relatives with breast cancer.  All female patients who underwent modified radical mastectomy, diagnosed with invasive ductal carcinoma and with HER-2/neu  Assay done at FEU-NRMF Medical Center from January to December 2012 were included.  The results of the HER-2/neu Assay were noted.  The pathology reports were used to determine the tumor size and lymp node status, which were classified using AJCC  (7th Edition)  Classification of Breast Carcinoma, and histological grade of the tumors, which were classified using the Nottingham Combined Histologic Grade  (The Elston-Ellis Modification of the Scarff-Bloom-Richardson Grading System) for Invasive Breast Carcinomas.  The hospital records of these patients were used to determine the age of the patient at the time of diagnosis and if these patients were used to determine the age of the patient at the time of diagnosis and if thesee patients have first-degree relatives with breast cancer.  The chisquare test was used to determine if there are significant associations relating HER-2/neu outcome with each of the clinicopathologic variables, patient`s age at the time of diagnosis and patient`s first-degree relatives with breast cancer.  All statistical tests were performed at 0.05 level of significance (95% confidence level).  One out of 3 cases had HER-2/neu overexpression . Thirteen percent have first degree relatives with breast cancer. However, the study found no sufficient statistical evidence to conclude significant association between HER-2/neu protein overexpression and large tumor size, high histologic tumor grade, number of positive lymph nodes, patient's age at the time of diagnosis and patient's first degree relatives with breast cancer
ER  -